The Latest Analyst Ratings For United Therapeutics
Portfolio Pulse from Benzinga Insights
United Therapeutics (NASDAQ:UTHR) has been the subject of diverse analyst ratings over the last three months, with a recent shift towards more bullish sentiments. The average 12-month price target for UTHR has risen to $311.14, marking a 4.06% increase from the previous target. The company, specializing in pulmonary arterial hypertension treatments, has shown a notable revenue growth of 25.07% over the past 3 months but faces challenges in net margin, ROE, and ROA compared to industry averages. Despite these challenges, its debt management is sound, with a low debt-to-equity ratio.
May 02, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics has received varied analyst ratings, with a recent trend towards more bullish views. The average price target has been raised to $311.14, reflecting a positive outlook on the company's financial performance and market position.
The increase in the average price target to $311.14, up from $299.00, indicates a positive sentiment among analysts, likely due to the company's significant revenue growth and sound debt management despite its challenges in profitability and asset utilization. This optimism among analysts could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100